Trade scPharmaceuticals Inc. - SCPH CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
scPharmaceuticals Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 4.64 |
Open* | 4.61 |
1-Year Change* | -51.98% |
Day's Range* | 4.38 - 4.61 |
52 wk Range | 4.63-12.75 |
Average Volume (10 days) | 219.91K |
Average Volume (3 months) | 7.44M |
Market Cap | 206.56M |
P/E Ratio | -100.00K |
Shares Outstanding | 35.86M |
Revenue | 7.50M |
EPS | -1.36 |
Dividend (Yield %) | N/A |
Beta | 0.02 |
Next Earnings Date | Mar 20, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 16, 2024 | 4.64 | -0.14 | -2.93% | 4.78 | 4.85 | 4.64 |
Apr 15, 2024 | 4.83 | -0.02 | -0.41% | 4.85 | 4.91 | 4.73 |
Apr 12, 2024 | 4.90 | -0.11 | -2.20% | 5.01 | 5.07 | 4.90 |
Apr 11, 2024 | 5.06 | 0.37 | 7.89% | 4.69 | 5.07 | 4.69 |
Apr 10, 2024 | 4.75 | -0.11 | -2.26% | 4.86 | 4.86 | 4.67 |
Apr 9, 2024 | 5.00 | 0.12 | 2.46% | 4.88 | 5.08 | 4.80 |
Apr 8, 2024 | 4.90 | 0.02 | 0.41% | 4.88 | 5.00 | 4.86 |
Apr 5, 2024 | 5.01 | -0.13 | -2.53% | 5.14 | 5.14 | 4.96 |
Apr 4, 2024 | 5.11 | 0.05 | 0.99% | 5.06 | 5.28 | 5.03 |
Apr 3, 2024 | 5.19 | 0.56 | 12.10% | 4.63 | 5.25 | 4.63 |
Apr 2, 2024 | 4.76 | 0.00 | 0.00% | 4.76 | 4.82 | 4.63 |
Apr 1, 2024 | 4.82 | -0.06 | -1.23% | 4.88 | 4.91 | 4.74 |
Mar 28, 2024 | 4.99 | 0.01 | 0.20% | 4.98 | 5.13 | 4.92 |
Mar 27, 2024 | 5.00 | 0.12 | 2.46% | 4.88 | 5.12 | 4.82 |
Mar 26, 2024 | 4.88 | 0.04 | 0.83% | 4.84 | 5.09 | 4.84 |
Mar 25, 2024 | 4.83 | -0.15 | -3.01% | 4.98 | 5.17 | 4.81 |
Mar 22, 2024 | 5.14 | -0.05 | -0.96% | 5.19 | 5.29 | 5.08 |
Mar 21, 2024 | 5.34 | -0.24 | -4.30% | 5.58 | 5.63 | 5.33 |
Mar 20, 2024 | 5.54 | 0.35 | 6.74% | 5.19 | 5.55 | 5.18 |
Mar 19, 2024 | 5.35 | 0.08 | 1.52% | 5.27 | 5.45 | 5.26 |
scPharmaceuticals Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, May 8, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q1 2024 scPharmaceuticals Inc Earnings Release Q1 2024 scPharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Wednesday, June 5, 2024 | ||
Time (UTC) 16:30 | Country US
| Event scPharmaceuticals Inc Annual Shareholders Meeting scPharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 36.157 | 25.823 | 29.933 | 32.905 | 29.667 |
Selling/General/Admin. Expenses, Total | 20.624 | 9.784 | 11.784 | 8.273 | 13.719 |
Research & Development | 15.533 | 16.039 | 18.149 | 24.632 | 15.948 |
Operating Income | -36.157 | -25.823 | -29.933 | -32.905 | -29.667 |
Interest Income (Expense), Net Non-Operating | -2.099 | -2.526 | -2.272 | -0.107 | 0.28 |
Other, Net | 1.418 | 0.315 | -0.004 | 0.016 | -0.056 |
Net Income Before Taxes | -36.838 | -28.034 | -32.209 | -32.996 | -29.443 |
Net Income After Taxes | -36.838 | -28.034 | -32.209 | -32.996 | -29.443 |
Net Income Before Extra. Items | -36.838 | -28.034 | -32.209 | -32.996 | -29.443 |
Net Income | -36.838 | -28.034 | -32.209 | -32.996 | -29.443 |
Income Available to Common Excl. Extra. Items | -36.838 | -28.034 | -32.209 | -32.996 | -29.443 |
Income Available to Common Incl. Extra. Items | -36.838 | -28.034 | -32.209 | -32.996 | -29.443 |
Dilution Adjustment | |||||
Diluted Net Income | -36.838 | -28.034 | -32.209 | -32.996 | -29.443 |
Diluted Weighted Average Shares | 28.3585 | 24.5689 | 24.5689 | 18.6007 | 18.5561 |
Diluted EPS Excluding Extraordinary Items | -1.29901 | -1.14104 | -1.31097 | -1.77391 | -1.5867 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | -1.29901 | -1.14104 | -1.31097 | -1.77391 | -1.5867 |
Total Extraordinary Items |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 1.638 | 2.063 | 0 | 0 | 0 |
Total Operating Expense | 15.384 | 13.617 | 9.502 | 9.995 | 9.421 |
Selling/General/Admin. Expenses, Total | 12.096 | 10.896 | 7.176 | 6.277 | 4.279 |
Research & Development | 2.934 | 2.116 | 2.326 | 3.718 | 5.142 |
Operating Income | -13.746 | -11.554 | -9.502 | -9.995 | -9.421 |
Interest Income (Expense), Net Non-Operating | -0.647 | -0.646 | -1.109 | -0.145 | -0.34 |
Other, Net | 0.239 | 0.99 | 1.363 | -0.022 | 0.064 |
Net Income Before Taxes | -14.154 | -11.21 | -9.248 | -10.162 | -9.697 |
Net Income After Taxes | -14.154 | -11.21 | -9.248 | -10.162 | -9.697 |
Net Income Before Extra. Items | -14.154 | -11.21 | -9.248 | -10.162 | -9.697 |
Net Income | -14.154 | -11.21 | -9.248 | -10.162 | -9.697 |
Income Available to Common Excl. Extra. Items | -14.154 | -11.21 | -9.248 | -10.162 | -9.697 |
Income Available to Common Incl. Extra. Items | -14.154 | -11.21 | -9.248 | -10.162 | -9.697 |
Diluted Net Income | -14.154 | -11.21 | -9.248 | -10.162 | -9.697 |
Diluted Weighted Average Shares | 38.6926 | 37.801 | 31.2857 | 27.4011 | 27.3785 |
Diluted EPS Excluding Extraordinary Items | -0.36581 | -0.29655 | -0.2956 | -0.37086 | -0.35418 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.36581 | -0.29655 | -0.2956 | -0.37086 | -0.35418 |
Revenue | 1.638 | 2.063 | |||
Cost of Revenue, Total | 0.354 | 0.605 | |||
Gross Profit | 1.284 | 1.458 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 123.308 | 78.275 | 107.826 | 75.647 | 91.893 |
Cash and Short Term Investments | 118.186 | 75.278 | 105.095 | 72.624 | 89.478 |
Cash & Equivalents | 71.061 | 74.268 | 71.819 | 72.624 | 89.478 |
Total Receivables, Net | 0.31 | 0.479 | |||
Prepaid Expenses | 2.282 | 2.791 | 2.61 | 2.619 | 1.757 |
Other Current Assets, Total | 1.61 | 0.206 | 0.121 | 0.094 | 0.179 |
Total Assets | 124.195 | 79.037 | 109.048 | 77.283 | 93.755 |
Property/Plant/Equipment, Total - Net | 0.62 | 0.479 | 0.908 | 1.306 | 1.67 |
Property/Plant/Equipment, Total - Gross | 0.808 | 0.649 | 1.044 | 1.408 | 2.27 |
Accumulated Depreciation, Total | -0.188 | -0.17 | -0.136 | -0.102 | -0.6 |
Other Long Term Assets, Total | 0.267 | 0.283 | 0.314 | 0.33 | 0.192 |
Total Current Liabilities | 7.416 | 14.846 | 9.321 | 5.237 | 6.673 |
Accounts Payable | 1.518 | 0.544 | 1.666 | 1.142 | 0.587 |
Accrued Expenses | 5.807 | 4.466 | 5.207 | 4.046 | 3.11 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.091 | 0.031 | 0.04 | 0.049 | 0.165 |
Total Liabilities | 51.762 | 22.567 | 26.878 | 25.918 | 15.011 |
Total Long Term Debt | 36.794 | 7.354 | 16.858 | 18.915 | 6.826 |
Other Liabilities, Total | 7.552 | 0.367 | 0.699 | 1.766 | 1.512 |
Total Equity | 72.433 | 56.47 | 82.17 | 51.365 | 78.744 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.003 | 0.003 | 0.003 | 0.002 | 0.002 |
Additional Paid-In Capital | 298.934 | 246.166 | 243.83 | 180.818 | 175.201 |
Retained Earnings (Accumulated Deficit) | -226.536 | -189.698 | -161.664 | -129.455 | -96.459 |
Total Liabilities & Shareholders’ Equity | 124.195 | 79.037 | 109.048 | 77.283 | 93.755 |
Total Common Shares Outstanding | 34.2579 | 27.3667 | 27.326 | 19.419 | 18.5693 |
Current Port. of LT Debt/Capital Leases | 0 | 9.805 | 2.408 | 0 | 2.811 |
Long Term Debt | 36.794 | 7.354 | 16.858 | 18.915 | 6.826 |
Short Term Investments | 47.125 | 1.01 | 33.276 | ||
Other Equity, Total | 0.032 | -0.001 | 0.001 | ||
Total Inventory | 1.23 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 104.339 | 113.574 | 126.667 | 123.308 | 47.169 |
Cash and Short Term Investments | 90.198 | 102.877 | 116.071 | 118.186 | 45.186 |
Cash & Equivalents | 35.042 | 71.35 | 75.453 | 71.061 | 41.289 |
Short Term Investments | 55.156 | 31.527 | 40.618 | 47.125 | 3.897 |
Prepaid Expenses | 1.579 | 1.835 | 2.685 | 2.282 | 1.643 |
Other Current Assets, Total | 1.264 | 1.42 | 1.286 | 1.61 | 0.34 |
Total Assets | 106.101 | 114.171 | 127.371 | 124.195 | 48.4 |
Property/Plant/Equipment, Total - Net | 1.574 | 0.408 | 0.514 | 0.62 | 0.739 |
Property/Plant/Equipment, Total - Gross | 1.78 | 0.608 | 0.708 | 0.808 | 0.919 |
Accumulated Depreciation, Total | -0.206 | -0.2 | -0.194 | -0.188 | -0.18 |
Other Long Term Assets, Total | 0.188 | 0.189 | 0.19 | 0.267 | 0.492 |
Total Current Liabilities | 10.951 | 6.635 | 7.735 | 7.416 | 17.176 |
Accounts Payable | 3.37 | 1.182 | 1.626 | 1.518 | 0.996 |
Accrued Expenses | 7.181 | 5.23 | 5.857 | 5.807 | 5.772 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 9.88 | |||
Other Current Liabilities, Total | 0.4 | 0.223 | 0.252 | 0.091 | 0.528 |
Total Liabilities | 56.955 | 50.744 | 51.564 | 51.762 | 17.29 |
Total Long Term Debt | 38.262 | 37.741 | 37.252 | 36.794 | 0 |
Long Term Debt | 38.262 | 37.741 | 37.252 | 36.794 | 0 |
Other Liabilities, Total | 7.742 | 6.368 | 6.577 | 7.552 | 0.114 |
Total Equity | 49.146 | 63.427 | 75.807 | 72.433 | 31.11 |
Common Stock | 0.004 | 0.004 | 0.004 | 0.003 | 0.003 |
Additional Paid-In Capital | 316.678 | 315.329 | 313.541 | 298.934 | 248.395 |
Retained Earnings (Accumulated Deficit) | -267.534 | -251.9 | -237.746 | -226.536 | -217.288 |
Other Equity, Total | -0.002 | -0.006 | 0.008 | 0.032 | 0 |
Total Liabilities & Shareholders’ Equity | 106.101 | 114.171 | 127.371 | 124.195 | 48.4 |
Total Common Shares Outstanding | 35.8591 | 35.8495 | 35.7691 | 34.2579 | 27.4021 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Total Inventory | 7.123 | 5.832 | 3.621 | 1.23 | |
Total Receivables, Net | 4.175 | 1.61 | 3.004 | ||
Accounts Receivable - Trade, Net | 4.175 | 1.61 | 3.004 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -36.838 | -28.034 | -32.209 | -32.996 | -29.443 |
Cash From Operating Activities | -34.577 | -27.151 | -27.693 | -30.442 | -28.812 |
Cash From Operating Activities | 0.037 | 0.034 | 0.034 | 0.037 | 0.038 |
Non-Cash Items | 2.574 | 3.448 | 3.034 | 2.163 | 2.803 |
Changes in Working Capital | -0.35 | -2.599 | 1.448 | 0.354 | -2.21 |
Cash From Investing Activities | -45.859 | 32.13 | -33.46 | 0 | |
Capital Expenditures | -0.021 | -0.009 | 0 | ||
Cash From Financing Activities | 77.229 | -2.53 | 60.348 | 13.588 | -0.008 |
Financing Cash Flow Items | -0.054 | -0.081 | -0.164 | 0 | |
Issuance (Retirement) of Stock, Net | 47.982 | 0.051 | 61.312 | 4.033 | 0.054 |
Issuance (Retirement) of Debt, Net | 29.301 | -2.5 | -0.8 | 9.555 | -0.062 |
Net Change in Cash | -3.207 | 2.449 | -0.805 | -16.854 | -28.82 |
Cash Taxes Paid | 0.19 | 0.206 | 0.226 | 0.337 | 0.298 |
Cash Interest Paid | 2.555 | 2.043 | 1.986 | 1.383 | 1.059 |
Other Investing Cash Flow Items, Total | -45.838 | 32.139 | -33.46 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -11.21 | -36.838 | -27.59 | -17.428 | -7.731 |
Cash From Operating Activities | -16.494 | -34.577 | -22.74 | -14.544 | -7.369 |
Cash From Operating Activities | 0.006 | 0.037 | 0.028 | 0.018 | 0.009 |
Non-Cash Items | 0.048 | 2.574 | 2.69 | 1.722 | 0.847 |
Cash Taxes Paid | 0.069 | 0.19 | 0.114 | 0.114 | 0.036 |
Cash Interest Paid | 1.485 | 2.555 | 1.099 | 0.794 | 0.425 |
Changes in Working Capital | -5.338 | -0.35 | 2.132 | 1.144 | -0.494 |
Cash From Investing Activities | 7 | -45.859 | -2.867 | -13.651 | -12.79 |
Other Investing Cash Flow Items, Total | 7 | -45.838 | -2.846 | -13.645 | -12.784 |
Cash From Financing Activities | 13.704 | 77.229 | -7.372 | -4.895 | -2.479 |
Financing Cash Flow Items | -0.054 | 0 | 0 | 0 | |
Issuance (Retirement) of Stock, Net | 13.704 | 47.982 | 0.128 | 0.105 | 0.021 |
Net Change in Cash | 4.21 | -3.207 | -32.979 | -33.09 | -22.638 |
Issuance (Retirement) of Debt, Net | 0 | 29.301 | -7.5 | -5 | -2.5 |
Capital Expenditures | 0 | -0.021 | -0.021 | -0.006 | -0.006 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
scPharmaceuticals Inc. Company profile
About Scpharmaceuticals Inc
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on exploring, developing and commercializing products that expand and advance the outpatient care of acute conditions, including worsening heart failure and bacterial infections requiring outpatient parenteral antimicrobial therapy. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infusor and is under development for treatment of congestion in patients with heart failure who display reduced responsiveness to oral diuretics and do not require hospitalization. Its area of focus is congestion in heart failure and outpatient parenteral antimicrobial therapy (OPAT). Its pipeline programs include FUROSCIX, scCeftriaxone and scCarbapenem. Its FUROSCIX On-Body Infusor is a drug-device combination product consisting of FUROSCIX. The Company's wholly owned subsidiary is scPharmaceuticals Securities Corporation.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Scpharmaceuticals Inc revenues was not reported. Net loss decreased 15% to $20.7M. Lower net loss reflects Research and development - Balancing decrease of 22% to $10.8M (expense), General and administrative - Balancing decrease of 9% to $6.6M (expense), Other income (expense) increase from $13K (expense) to $298K (income).
Industry: | Pharmaceuticals (NEC) |
2400 District Avenue
Suite 310
BURLINGTON
MASSACHUSETTS 01803
US
Income Statement
- Annual
- Quarterly
News
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com